ES2089687T3 - 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa. - Google Patents

4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.

Info

Publication number
ES2089687T3
ES2089687T3 ES93119766T ES93119766T ES2089687T3 ES 2089687 T3 ES2089687 T3 ES 2089687T3 ES 93119766 T ES93119766 T ES 93119766T ES 93119766 T ES93119766 T ES 93119766T ES 2089687 T3 ES2089687 T3 ES 2089687T3
Authority
ES
Spain
Prior art keywords
phenyl
piridones
alcoxipiridinas
substituted
reductasa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93119766T
Other languages
English (en)
Inventor
Rolf Dr Angerbauer
Peter Dr Fey
Walter Dr Hubsch
Thomas Dr Philipps
Hilmar Dr Bischoff
Hans Peter Dr Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4321421A external-priority patent/DE4321421A1/de
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2089687T3 publication Critical patent/ES2089687T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

3-FENILPIRIDONAS Y 4-FENILPIRIDINAS SUSTITUIDAS SE PRODUCEN, POR REDUCCION DE LOS CORRESPONDIENTES DERIVADOS 4-FENILO-PIRIDONAS POR EJEMPLO DERIVADOS 4-FENILOALCOXIPIRIDINAS. LAS 4-FENIL-PIRIDONAS Y 4-FENIL-2-ALCOXIPIRIDINAS SUSTITUIDAS PUEDEN EMPLEARSE COMO SUSTANCIAS ACTIVAS EN MEDICAMENTOS, PARTICULARMENTE PARA EL TRATAMIENTO DE HIPERLIPOPROTEINEMIA.
ES93119766T 1992-12-21 1993-12-08 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa. Expired - Lifetime ES2089687T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4243278 1992-12-21
DE4321421A DE4321421A1 (de) 1992-12-21 1993-06-28 Substituierte 4-Phenyl-pyridone und 4-Phenyl-2-alkoxypyridine

Publications (1)

Publication Number Publication Date
ES2089687T3 true ES2089687T3 (es) 1996-10-01

Family

ID=25921579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93119766T Expired - Lifetime ES2089687T3 (es) 1992-12-21 1993-12-08 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.

Country Status (21)

Country Link
US (1) US5418243A (es)
EP (1) EP0603649B1 (es)
JP (1) JPH06234741A (es)
CN (1) CN1117965A (es)
AT (1) ATE140226T1 (es)
AU (1) AU660132B2 (es)
CA (1) CA2111778A1 (es)
CZ (1) CZ284093A3 (es)
DE (1) DE59303195D1 (es)
DK (1) DK0603649T3 (es)
ES (1) ES2089687T3 (es)
FI (1) FI935728A (es)
GR (1) GR3020668T3 (es)
HU (1) HUT70150A (es)
IL (1) IL108071A0 (es)
MX (1) MX9308013A (es)
NO (1) NO934706L (es)
NZ (1) NZ250500A (es)
PH (1) PH29953A (es)
PL (1) PL301582A1 (es)
SK (1) SK144893A3 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627420A1 (de) * 1996-07-08 1998-01-15 Bayer Ag 6-(Hydroxymethyl-ethyl)pyridine
JP2005126340A (ja) * 2003-10-22 2005-05-19 Kureha Chem Ind Co Ltd 置換ピリドン類の製造法、その原料化合物及びその製造方法
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR101520086B1 (ko) * 2007-09-14 2015-05-14 얀센 파마슈티칼스 인코포레이티드 1´,3´-이치환된-4-페닐-3,4,5,6-테트라히드로-2h,1´h-[1,4´]비피리디닐-2´-온
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
NZ584148A (en) * 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
JP5433582B2 (ja) * 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. イミダゾ[1,2−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
AU2010246607B2 (en) 2009-05-12 2012-09-27 Addex Pharma S.A. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
CN104370806B (zh) * 2014-06-17 2017-07-07 中国海洋大学 一种吡啶酮生物碱类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4156727A (en) * 1975-07-31 1979-05-29 Smith Kline & French Laboratories Limited Alkoxy pyridine compounds
GB1564502A (en) * 1975-07-31 1980-04-10 Smith Kline French Lab Guanidines thioureas and 1,1-diamino-2-nitroethylene derivatives
US4684477A (en) * 1985-03-06 1987-08-04 Chisso Corporation Pyridine derivatives and their use in liquid crystals
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0339342A1 (de) * 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5032602A (en) * 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
DE3909378A1 (de) * 1989-03-22 1990-09-27 Bayer Ag Substituierte biphenyle
DE3925636A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Imino-substituierte pyridine

Also Published As

Publication number Publication date
NZ250500A (en) 1996-02-27
CZ284093A3 (en) 1994-07-13
AU660132B2 (en) 1995-06-08
CA2111778A1 (en) 1994-06-22
JPH06234741A (ja) 1994-08-23
HU9303675D0 (en) 1994-04-28
DE59303195D1 (de) 1996-08-14
DK0603649T3 (da) 1996-11-04
EP0603649B1 (de) 1996-07-10
US5418243A (en) 1995-05-23
PL301582A1 (en) 1994-06-27
FI935728A0 (fi) 1993-12-20
CN1117965A (zh) 1996-03-06
AU5195593A (en) 1994-06-30
ATE140226T1 (de) 1996-07-15
MX9308013A (es) 1994-08-31
SK144893A3 (en) 1995-02-08
NO934706L (no) 1994-06-22
HUT70150A (en) 1995-09-28
NO934706D0 (no) 1993-12-20
EP0603649A1 (de) 1994-06-29
FI935728A (fi) 1994-06-22
IL108071A0 (en) 1994-04-12
PH29953A (en) 1996-09-16
GR3020668T3 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
MX9300766A (es) Piridonas sustituidas por sulfonilbencilo, procedimiento para su obtencion y medicamentos que las contienen.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
GEP19991834B (en) Crystalline Oxathiolane Derivatives
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
ES2147320T3 (es) Derivados de n-(3-benzofuranil)urea.
SV1994000071A (es) Procedimiento de una etapa para la fabricacion de derivados de acido 3-quinoloncarboxilico, ref. le a 29 572-sv.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
MX9207557A (es) Derivados de acidos benzofuranil- y tiofenilmetiltio-alcanocarboxilicos, procedimiento para su preparacion y medicamentos que los contienen.
MX9302487A (es) Piridonas sustituidas por bifenilmetilo, procedimiento para su obtencion y medicamentos que las contienen.
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
ES2058343T3 (es) Piridinas disubstituidas.
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
DE59107336D1 (de) Oligosaccharidderivate und deren Verwendung in Heilmitteln
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
ATE255567T1 (de) Benzoxazin- und benzothiazin-derivate und deren verwendung in arzneimitteln
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 603649

Country of ref document: ES

FG2A Definitive protection

Ref document number: 603649

Country of ref document: ES